Real-World Outcomes and Prognostic Factors in Patients Receiving Nivolumab Therapy for Recurrent or Metastatic Head and Neck Carcinoma.
Hori R, Shinohara S, Kojima T, Kagoshima H, Kitamura M, Tateya I, Tamaki H, Kumabe Y, Asato R, Harada H, Kitani Y, Tsujimura T, Honda K, Ichimaru K, Omori K.
Hori R, et al. Among authors: kagoshima h.
Cancers (Basel). 2019 Sep 6;11(9):1317. doi: 10.3390/cancers11091317.
Cancers (Basel). 2019.
PMID: 31500103
Free PMC article.